Geode Capital Management LLC raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,700,782 shares of the company's stock after purchasing an additional 259,010 shares during the quarter. Geode Capital Management LLC owned approximately 2.17% of Vaxcyte worth $308,675,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in the business. Blue Trust Inc. boosted its holdings in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after acquiring an additional 93 shares during the period. Nisa Investment Advisors LLC boosted its stake in Vaxcyte by 5.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company's stock valued at $252,000 after purchasing an additional 110 shares during the period. CIBC Asset Management Inc grew its holdings in Vaxcyte by 3.6% in the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company's stock valued at $358,000 after buying an additional 110 shares in the last quarter. Amalgamated Bank increased its position in Vaxcyte by 4.2% during the 2nd quarter. Amalgamated Bank now owns 3,759 shares of the company's stock worth $284,000 after buying an additional 150 shares during the period. Finally, Riverview Trust Co acquired a new stake in shares of Vaxcyte during the third quarter worth $27,000. Institutional investors and hedge funds own 96.78% of the company's stock.
NASDAQ PCVX opened at $87.72 on Friday. The business has a fifty day moving average price of $101.11 and a two-hundred day moving average price of $91.68. The stock has a market capitalization of $10.93 billion, a PE ratio of -19.07 and a beta of 0.94. Vaxcyte, Inc. has a fifty-two week low of $53.83 and a fifty-two week high of $121.06.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the company earned ($0.91) EPS. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.
In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company's stock, valued at $10,479,005.02. This represents a 8.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $92.25, for a total value of $218,263.50. Following the sale, the chief executive officer now directly owns 136,215 shares in the company, valued at $12,565,833.75. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 117,830 shares of company stock valued at $12,600,310. 3.10% of the stock is currently owned by insiders.
Several equities analysts recently commented on the stock. Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. BTIG Research raised their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reissued a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Bank of America lifted their price objective on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte currently has a consensus rating of "Buy" and an average price target of $147.50.
View Our Latest Report on Vaxcyte
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.